Aesica plans global expansion with debt
This article was originally published in Scrip
Executive Summary
Private equity group Silverfleet Capital has acquired a majority position in Aesica Pharmaceuticals ,,the UK-headquartered contract pharmaceutical formulator and manufacturer, by buying the stake owned by LDC, the private equity arm of Lloyds Bank. Members of Aesica's executive team have also agreed to reinvest a significant amount to secure a large minority stake. Debt, provided by Lloyds, HSBC and Yorkshire Bank, will be used to underwrite the company's international expansion ambitions, particularly in the US.